Clinical Trial Update: A Safety and Tolerability Study of REGN88(SAR153191) in Subjects With Rheumatoid Arthritis [Phase 1]

View source ↗

Summary

Phase 1 trial update shows safety and tolerability data for REGN88 (SAR153191) in subjects with rheumatoid arthritis; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• REGN88 (SAR153191) (SAR153191)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Rheumatoid Arthritis | Phase 1 | Status: COMPLETED